Here are the DEF 14A proxy statements from Citius Pharmaceuticals Inc. (CTXR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CTXR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTXR filings page.
Citius Pharmaceuticals is asking stockholders to vote at its April 6, 2026 annual meeting on electing seven directors for one-year terms and ratifying Wolf & Company, P.C. as auditor for the fiscal year ending September 30, 2026.
Stockholders of record as of February 13, 2026, when 22,376,427 common shares were outstanding, are entitled to one vote per share. A majority of votes represented and entitled to vote is required to elect directors and ratify the auditor. The board reports that five of seven director nominees are independent under Nasdaq rules and highlights its committee structure, executive and director pay practices, and employment and severance arrangements for senior management.